{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:25:26Z","timestamp":1769599526109,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000271","name":"Science and Technology Facilities Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clon.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T17:34:13Z","timestamp":1657560853000},"page":"e1-e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["An Update to the Malthus Model for Radiotherapy Utilisation in England"],"prefix":"10.1016","volume":"35","author":[{"given":"S.","family":"Heritage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.F.","family":"Kirkby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.J.","family":"Kirkby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Jena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2022.06.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clon.2011.11.009","article-title":"The Malthus programme \u2013 a new tool for estimating radiotherapy demand at a local level","volume":"24","author":"Jena","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.clon.2013.05.006","article-title":"The Malthus Programme: developing radiotherapy demand models for breast and prostate cancer at the local, regional and national level","volume":"25","author":"Round","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2016.11.014","article-title":"Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer","volume":"122","author":"Sanderson","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib4","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.clon.2021.03.004","article-title":"Variations in demand across England for the magnetic resonance-linac technology, simulated utilising local-level demographic and cancer data in the Malthus Project","volume":"33","author":"Mee","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clon.2013.05.005","article-title":"Radiotherapy demand and activity in England 2006\u20132020","volume":"25","author":"Round","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clon.2014.11.003","article-title":"Quantifying uncertainty in radiotherapy demand at the local and national level using the Malthus model","volume":"27","author":"Jena","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib7","series-title":"Mendeley Data","article-title":"Malthus 2021 update and results","author":"Mee","year":"2022"},{"key":"10.1016\/j.clon.2022.06.006_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial). 5 year results from multicentre, randomised, controlled, phase 3 non-inferiority trial","volume":"390","author":"Coles","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2022.06.006_bib10","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150453","article-title":"Clinical impact of IMPORT HIGH trial (CRUK\/06\/003) on breast radiotherapy practices in the United Kingdom","volume":"88","author":"Tsang","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clon.2022.06.006_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-GS4-05","article-title":"Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK\/06\/003) [abstract]","volume":"79","author":"Coles","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2022.06.006_bib12","series-title":"Postoperative radiotherapy for breast cancer: UK consensus statements","author":"The Royal College of Radiologists","year":"2016"},{"key":"10.1016\/j.clon.2022.06.006_bib13","author":"The Royal College of Radiologists"},{"key":"10.1016\/j.clon.2022.06.006_bib14","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2022.06.006_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clon.2020.03.006","article-title":"International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic","volume":"32","author":"Coles","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41571-020-0375-1","article-title":"Cancer and COVID-19 \u2013 potentially deleterious effects of delaying radiotherapy","volume":"17","author":"Nagar","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.adro.2020.03.011","article-title":"Adapting radiation therapy treatments for patients with breast cancer during the COVID-19 pandemic: hypo-fractionation and accelerated partial breast irradiation to address World Health Organization Recommendations","volume":"5","author":"Al-Rashdan","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijrobp.2020.06.041","article-title":"COVID-19: a catalyst for change for UK clinical oncology","volume":"108","author":"Coles","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2022.06.006_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.06.006_bib21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2022.06.006_bib24","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2022.06.006_bib26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib27","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib28","author":"SABR Consortium"},{"key":"10.1016\/j.clon.2022.06.006_bib29","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.21037\/tlcr.2019.07.09","article-title":"Changing equipoise in the landscape of radiation for oligometastatic lung cancer","volume":"8","author":"Schroeder","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.clon.2022.06.006_bib30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13014-018-1133-8","article-title":"Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis","volume":"13","author":"Matuschek","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.radonc.2017.12.011","article-title":"Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: a systematic review","volume":"126","author":"Shahid Iqbal","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib33","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/cncr.32968","article-title":"Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: the Princess Margaret experience and proposal","volume":"126","author":"Huang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2022.06.006_bib35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/bjc.2016.304","article-title":"Cancer incidence and mortality projections in the UK until 2035","volume":"115","author":"Smittenaar","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2022.06.006_bib36","author":"Office for National Statistics"},{"key":"10.1016\/j.clon.2022.06.006_bib37","author":"NICE guidelines"},{"key":"10.1016\/j.clon.2022.06.006_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.radonc.2015.01.001","article-title":"The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies","volume":"114","author":"Nilsson","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-018-1019-5","article-title":"The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","volume":"16","author":"Gnanapragasam","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.clon.2022.06.006_bib40","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clon.2019.07.020","article-title":"Stage III non-small cell lung cancer management in England","volume":"31","author":"Adizie","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.006_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020690","article-title":"Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2022.06.006_bib43","article-title":"Introduction to the United Kingdom National Multidisciplinary Guidelines for Head and Neck Cancer","volume":"130","author":"Paleri","year":"2016","journal-title":"J\u00a0Laryngol Otol"},{"key":"10.1016\/j.clon.2022.06.006_bib44","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1017\/S0022215116000529","article-title":"Hypopharyngeal cancer: United Kingdom national multidisciplinary guidelines","volume":"130","author":"Pracy","year":"2016","journal-title":"J\u00a0Laryngol Otol"},{"key":"10.1016\/j.clon.2022.06.006_bib45","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522002783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522002783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:46Z","timestamp":1760543566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522002783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0936655522002783"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.06.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update to the Malthus Model for Radiotherapy Utilisation in England","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}